Johnson & Johnson

JNJ

买入
2026年7月27日Neutral

决策摘要

The at 18.67 reflects a neutral-to-cautious market regime, while the 10-year yield at 4.64% continues to compress defensive multiples, but JNJ's low beta and income profile provide relative resilience. Fundamentally, Q2 adjusted of $2.90 beat estimates by 1.6%, and full-year guidance was raised for the second time; FY2026 consensus has risen from $11.57 to $11.68 over the past 30 days. The forward of 20.7x is slightly below the 5-year average, offering reasonable value for a high-quality compounder. Technically, the stock is in a strong uptrend above the 50-day ($246.21) and 200-day ($220.97), with histogram turning positive and at 64.6, indicating improving momentum. is rising, confirming accumulation. The FDA De Novo authorization for the Ottava robotic surgery system on July 22 provides a major new catalyst in MedTech, and multiple analyst price target raises (mean $270.59, 1.7% upside) support the thesis. Insider selling by senior executives remains a caution, but the Director's purchase in July provides a slight offset. The key risk is talc litigation uncertainty, but the pipeline strength and new product launches position JNJ for durable compounding. The 2.03% dividend yield and 64-year growth streak provide an income anchor. Overall, the setup is constructive with a bullish technical posture and positive fundamental revisions, warranting a BUY rating.

投资判断

实时价格

$265.95

推荐分数

75%
75%

置信度

75%
75%

各期限展望

1个月

买入

短线

6个月

买入

中期

1年

买入

长期

核心催化

FDA authorization of Ottava robotic surgery system on July 22, which positions JNJ in the fast-growing surgical robotics market and could drive meaningful revenue from 2027.

稳定性分类Defensive Compounder组合角色Core Anchor回撤风险Low风险画像ConservativeDividend KingOttava ApprovalUpward RevisionsTalc OverhangInsider SellingMedTech RoboticsPipeline Momentum
决策工作台

价格地图

60日设置

价格轨道

$265.95
止损
当前
$241
$257
$273
$289
止损位

$245.00

买入

$255.00 - $262.00

止盈

$270.00 - $285.00

风险/回报

2.0x

有吸引力

到止损下行

-7.9%

到止盈上行

+7.2%

仓位提示

Given the slightly above 18 and positive catalyst momentum, a normal-sized position is appropriate for long-term investors. Traders may consider adding on pullbacks to the 50-day ($246) or the $255 area.

投资逻辑快照

什么情况涨

JNJ offers a rare combination of defensive stability, strong pipeline momentum, and a 64-year dividend growth streak. The Q2 beat and raised guidance demonstrate operational resilience. The Ottava robotic surgery approval opens a new high-growth MedTech avenue. With a forward of 20.7x and AAA credit rating, the stock is reasonably valued for long-term compounding. Upward estimate revisions and analyst upgrades confirm improving sentiment.

什么情况跌

Talc litigation overhang remains unresolved, with potential for larger verdicts or a multi-billion settlement. Stelara biosimilar erosion could pressure earnings for years, as seen in the 55% Q2 sales decline. The high (4.36) suggests limited near-term growth relative to valuation. Insider selling by CEO and CFO raises caution. MedTech weakness in Cardiovascular may persist, and Ottava adoption could be slower than expected in a market dominated by Intuitive Surgical.

A sustained break and close below the 50-day ($246.21) and the $245 support level would invalidate the near-term bullish setup and suggest a deeper correction toward the 200-day ($220.97).

  • Talc litigation costs exceeding current reserves, e.g., a large jury award or forced settlement exceeding $1B.
  • Stelara biosimilar erosion accelerating faster than expected, causing further revenue declines in immunology.
  • Broader market risk-off shift or rising yields compressing defensive multiples further.
  • MedTech weakness, particularly in Cardiovascular devices, if competitive pressures or procedure volume uncertainty persist.
  • Insider selling by senior executives may indicate near-term headwinds.

接下来关注

  • 下一次财报：2026年10月13日
  • FDA authorization of Ottava robotic surgery system on July 22, which positions JNJ in the fast-growing surgical robotics market and could drive meaningful revenue from 2027.
信号仪表盘

决策输入

6 个信号

基本面

1.8%

距分析师均值目标空间

JNJ trades at a forward of 20.7x, slightly below its 5-year average of ~21x and near the sector median. The ratio of 4.36 reflects near-term earnings pressure from Stelara biosimilar erosion, but long-term pipeline visibility supports a fair valuation. of 19.0x is in line with large-cap pharma peers. The mean analyst target of $270.59 implies only 1.7% upside from $265.95, but the wide range ($190-$305) highlights talc litigation uncertainty. After the Ottava approval, MedTech growth narrative improves, potentially supporting multiple expansion. For a high-quality defensive compounder, current multiples offer reasonable entry for long-term investors.

技术面

Bullish

趋势质量

Price ($265.95) remains above the 200-day ($220.97) and 50-day ($246.21). The golden cross ( > ) has been intact since June. The stock pulled back from $269.43 on July 7 to a low of $245.49 on July 15, then bounced sharply, reclaiming the 20-day ($257.04). The longer-term trend is bullish, with the bounce off the 50-day confirming support.

财报

77天

Steady

Q2 2026 adjusted of $2.90 beat estimates of $2.85 by 1.6%; revenue of $25.31B beat consensus of $25.18B; full-year guidance was raised for the second time, and the stock has since recovered on positive analyst reactions and the Ottava approval.

新闻

Bullish

新闻基调

FDA authorization of Ottava robotic surgery system on July 22, which positions JNJ in the fast-growing surgical robotics market and could drive meaningful revenue from 2027.

宏观

Neutral

4.64% 10Y / 18.7 VIX

at 18.67 indicates a neutral-to-cautious environment; rising 10-year yields (4.64%) modestly compress defensive multiples, but JNJ's low beta (0.23) and 2.03% dividend yield provide relative resilience.

稳定性

Defensive Compounder

Core Anchor

Johnson & Johnson is a quintessential defensive compounder with an AAA credit rating, 64-year dividend growth streak, low beta of 0.23, and diversified healthcare revenue across pharmaceuticals and MedTech. Its strong free cash flow generation and high institutional ownership (76.8%) provide stability. The recent FDA approval of the Ottava robotic surgical system opens a new MedTech growth avenue, while the pharmaceutical pipeline, including DARZALEX and CARVYKTI, sustains above-market growth. Drawdown risk is limited by structural support near the 50-day ($245) and a resilient balance sheet, though talc litigation and Stelara erosion require monitoring. This stock is suitable as a Core Anchor for conservative long-term investors seeking reliable income and capital preservation.

分析师目标区间

均值目标

$270.59

高低目标

$190 / $305

分析师中值目标

$274.00

共识区间

$190 - $305

— 位分析师
Mean
$190$271$305

市场共识

Consensus shows 5 Strong Buy, 11 Buy, 6 Hold, 1 Sell (total 23 analysts). The mean target of $270.59 implies 1.7% upside, with a spread from $190 to $305, reflecting talc litigation uncertainty. The number of Buy-rated analysts and recent upward revisions indicate improving sentiment. The Ottava catalyst and raised guidance have solidified buy-side conviction.

筹码脉冲

内部人信号

Moderate Sell

净偏向

Sell-heavy

内部人持股

0.0%

机构持股

76.8%

解读

Recent insider selling by senior executives outweighs buying, suggesting near-term caution, though the CEO and CFO sales may be pre-planned. The small director purchase is a positive but insufficient signal to offset the selling.

重要活动

CEO Joaquin Duato sold $12.6M in shares (likely pre-planned). CFO Joseph Wolk exercised and sold 68,890 shares (tax-related). COO Kathryn Wengel sold $3.28M. Director Mark Weinberger purchased $147k in open market.

市场背景

行业

Drug Manufacturers - General

Mixed-Bullish

情绪

34

跟踪股票

5

分组

industry

Drug Manufacturers - General 行业 当前情绪为 Mixed-Bullish，板块平均评分约 64 分，资金与评分正在同步走强，且leadership is concentrated in LLY, ABBV, NVO。

轮动线索

  • Drug Manufacturers - General 行业 组内平均推荐分数正在上修，说明资金偏好有扩散迹象。
  • 当前组内偏多评级 4 只，偏空评级 0 只，可见情绪主导方向为 Mixed-Bullish。
  • 核心观察名单集中在 LLY、ABBV、NVO，这些股票更能代表板块资金风向。

重点龙头股

相关龙头股

  • LLY

    Eli Lilly and Company

    Leader

    评分

    58

    价格

    $1197.53

    市值

    $1.07T

  • ABBV

    AbbVie Inc.

    Leader

    评分

    73

    价格

    $256.91

    市值

    $453.91B

  • NVO

    Novo Nordisk A/S

    High Momentum

    评分

    45

    价格

    $49.67

    市值

    $219.68B

  • AMGN

    Amgen Inc.

    High Momentum

    评分

    68

    价格

    $376.26

    市值

    $203.07B

主题

Next-Gen Oncology and Immunotherapy

评分: 65

Bullish

JNJ's oncology portfolio is a key growth driver, with DARZALEX, CARVYKTI, and TECVAYLI gaining share. The company is a leader in CAR-T and bispecific antibodies. Q2 results highlighted strong performance of Tremfya (+72.5%) and successful launches of ICOTYDE and INLEXZO. The pipeline continues to offset Stelara erosion.

The Q2 earnings call underscored strong commercial execution in oncology and immunology, with Tremfya and new drug launches driving above-consensus pharma sales.

  • Increasing adoption of CAR-T and bispecific therapies in earlier treatment lines
  • Expanding labels for DARZALEX and CARVYKTI driving sustained revenue growth

MedTech Robotics

评分: 60

Mixed-Bullish

JNJ's entry into robotic surgery with the Ottava system positions it to compete in a growing market dominated by Intuitive Surgical. The FDA authorization covers soft-tissue procedures. Adoption may be gradual, and the competitive landscape is intense, but JNJ's commercial scale and hospital relationships provide an edge. Q2 MedTech growth slowed to 4.5%, but Vision, Orthopedics, Surgery accelerated.

The FDA De Novo authorization of Ottava on July 22 provides a new growth catalyst in surgical robotics.

  • Rising preference for minimally invasive surgeries and robotic assistance
  • JNJ's strong track record in commercializing MedTech products and extensive hospital network
关键指标
23 项指标

市值

$640.91B

市盈率 (TTM)

30.9

远期市盈率

20.7

营收增速

6.6%

净资产收益率

25.7%

Beta 系数

0.23

完整指标集

另外 17 项指标

估值结构

估值倍数与现金流框架。

市销率

6.5

市净率

7.5

企业价值 / EBITDA

19.0

质量与资产负债表

利润率、杠杆与流动性。

毛利率

68.1%

营业利润率

29.2%

资产负债率

57.7

流动比率

1.09x

速动比率

0.73x

仓位与价格区间

空头仓位与52周区间位置。

流通盘空头占比

1.3%

空头回补天数

3.04x

52周最高

$269.43

52周最低

$164.23

距52周高点

-1.3%

距52周低点

61.9%

公司分类

板块与行业背景。

板块

Healthcare

行业

Drug Manufacturers - General

其他信号

自由现金流

$16885125120.00

详细分析
估值
JNJ trades at a forward of 20.7x, slightly below its 5-year average of ~21x and near the sector median. The ratio of 4.36 reflects near-term earnings pressure from Stelara biosimilar erosion, but long-term pipeline visibility supports a fair valuation. of 19.0x is in line with large-cap pharma peers. The mean analyst target of $270.59 implies only 1.7% upside from $265.95, but the wide range ($190-$305) highlights talc litigation uncertainty. After the Ottava approval, MedTech growth narrative improves, potentially supporting multiple expansion. For a high-quality defensive compounder, current multiples offer reasonable entry for long-term investors.
资产负债表
Strong balance sheet with a debt-to-equity ratio of 57.7%, manageable net debt of $28.3B, and robust cash generation from operations of $27.6B. The AAA credit rating ensures low-cost capital access. Free cash flow yield of 2.6% is adequate for the sector, supporting dividends and strategic investments.
增长
Revenue growth of 6.6% YoY in Q2, driven by oncology (DARZALEX, CARVYKTI) and immunology (Tremfya +72.5%). MedTech grew 4.5%, with strength in Vision, Orthopedics, and Surgery offsetting Cardiovascular softness. Adjusted grew 4.7% in Q2. Guidance for FY2026 raised to $11.68 midpoint. Long-term growth is supported by pipeline including ICOTYDE, nipocalimab, and the Ottava launch. The company expects to surpass $100B in revenue in 2026.

生意质量

Gross margin of 68.1%, operating margin of 29.2%, and margin of 35.6% reflect strong pricing power and operational efficiency. of 25.7% demonstrates capital efficiency. High switching costs, regulatory barriers, and broad diversification across pharma and MedTech support durable competitive advantages.

资本配置

Management prioritizes dividend growth (64 years, $5.40 annual dividend, 60.8% payout ratio) and strategic bolt-on M&A. Share count has remained stable. The dividend yield of 2.03% is sustainable. Recent capital allocation has been shareholder-friendly, with debt reduction and moderate buybacks implied by stable share count.

预期修正

estimates for FY2026 have been revised up from $11.57 to $11.68 over the past 30 days, and FY2027 from $12.70 to $12.83. Upward revisions outnumber downgrades in the last 7 days (2 up, 0 down). Recent analyst actions include price target raises from Raymond James, Wells Fargo, and Morgan Stanley. Revision momentum is clearly positive.

营收增速

6.6%

实时动态与情绪

内部活动

  • DECKER ROBERT J

    Officer

    5,635

    $564k

  • BROADHURST VANESSA

    Officer

    9,809

    —

  • WOODS EUGENE A

    Director

    100

    $15k

  • DECKER ROBERT J

    Officer

    5,635

    $930k

新闻催化剂

2026年7月27日

Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its full-year guidance and is on track to surpass $100 billion […]

2026年7月27日

UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch

UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.

2026年7月27日

🔎 Under the Radar: Legend Stock Tumbles After CEO Departs

Shares of Legend Biotech fell 14% Monday after the company announced that CEO Ying Huang stepped down and left the board. Legend said in a regulatory filing that Huang’s resignation was not the result of a disagreement with the company, but didn’t say anything more about why he left. Huang said he was departing the company to work with a venture fund focusing on drug development.

2026年7月27日

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.